Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial

被引：0

作者：

Billings, Liana K.

Doshi, Ankur

Gouet, Didier

Oviedo, Alejandra

Rodbard, Helena W.

Tentolouris, Nikolaos

Gron, Randi

Halladin, Natalie

Jodar, Esteban

机构：

来源：

DIABETES | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

136-OR

引用

页码：A36 / A36

页数：1

共 50 条

[11] Treatment Patterns and Characteristics of Patients with Type 2 Diabetes (T2D) Managed with Basal-Bolus Therapy in the
Van Brunt, Kate
Curtis, Bradley H.
Chalkiadaki, Corina
Balogh, Elemer
Ivanyi, Tibor
Raluy, Mireia
Maclachlan, Sharon
DIABETES, 2015, 64 : A696 - A697
[12] Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target-Analyses from the DUAL Program
Meneghini, Luigi
Linjawi, Sultan
Serusclat, Pierre
Vilsboll, Tina
Agner, Bue F.
Hansen, Trine
Leiter, Lawrence A.
DIABETES, 2018, 67
[13] Efficacy and Safety of Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in Hispanic Patients with Type 2 Diabetes (T2D)
Chaykin, Louis B.
Bhargava, Anuj
Wysham, Carol H.
Abrahamsen, Trine
Van Leeuwen, Michiel
De la Rosa, Raymond
DIABETES, 2017, 66 : A617 - A617
[14] Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)
Falcetta, Pierpaolo
Indovina, Francesco S.
Giannarelli, Rosa
Piaggesi, Alberto
Penno, Giuseppe
Miccoli, Roberto
Del Prato, Stefano
Coppelli, Alberto
DIABETES, 2019, 68
[15] Efficacy and safety of a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes after 1 year of treatment
Gough, S. C. L.
Woo, V. C.
Rodbard, H. W.
Linjawi, S.
Poulsen, P.
Korsholm, L.
Bode, B. W.
DIABETIC MEDICINE, 2015, 32 : 76 - 76
[16] Insulin Degludec: Reduction of Hypoglycemia during Basal-Bolus Therapy in Patients with Diabetes Mellitus Type 1 or 2
Luedemann, J.
Merker, L.
Milek, K.
Kaiser, M.
Wilhelm, B.
DIABETOLOGIE UND STOFFWECHSEL, 2013, 8 (01) : 35 - 42
[17] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
Vedtofte, Louise
Knop, Filip K.
Vilsboll, Tina
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
[18] Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%-Analyses from the DUAL Program
Sugimoto, Danny
Frias, Juan P.
Gouet, Didier
Takacs, Robert
Jia, Ting
Orsy, Petra
Bain, Stephen C.
DIABETES, 2018, 67
[19] Efficacy and safety of prandial premixed (ILPS/lispo) vs basal bolus (glargine/lispro) insulin therapy in Hispanic and African American patients with type 2 diabetes (T2D)
Colon, Gildred
Jiang, Honghua
Martin, Sherry A.
DIABETES, 2008, 57 : A143 - A144
[20] An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin
Evans, Marc
Billings, Liana K.
Hakan-Bloch, Jonas
Slothuus, Ulla
Abrahamsen, Trine J.
Andersen, Andreas
Jansen, Jeroen P.
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (04) : 340 - 347

← 1 2 3 4 5 →